The rare disease biotech announced the FDA has accepted its supplemental New Drug Application to expand Voxzogo (vosoritide) to children younger than five years.
Posts
Rare disease biotech BioMarin Pharmaceuticals Inc. announced Friday it was shedding around 4% of its global workforce, or around 120 jobs, in an effort to improve its operational efficiency.